Contrast Media
Contrast media, also called contrast agents, are used to enhance the blood and perfusion in tissues. This includes iodine based contrast for on computed tomography (CT), gadolinium based agents for MRI and lipid bubble contrast agents used in ultrasound.
Gadolinium-based contrast agents (GBCAs) used in MRI causes gadolinium retention in the brain, skin and bone. However, there have not been any large-scale studies to determine if this presents long-term patient safety issues.
Blog | Magnetic Resonance Imaging (MRI) | December 15, 2017 | Dave Fornell
Over the past couple years covering the news about gadolinium-based contrast agent (GBCA) retention in the brain, skin...
Technology | Contrast Media | December 12, 2017
December 12, 2017 — Brainlab announced U.S. Food and Drug Administration (FDA) clearance of its Contrast Clearance...
Technology | Contrast Media | December 11, 2017
December 11, 2017 — Sectra recently announced the global introduction of gadolinium tracking in its dose monitoring...
Sponsored Content
A volume of contrast agent lingers near the injection site, creating an artifact that can block the visualization of structures. Graphic courtesy of Lior Molvin
Blog | Contrast Media | October 15, 2019
When it comes to listing needs, patient safety ranks at the top. Just ask an imaging administrator.
“There is no way we...
Videos | Magnetic Resonance Imaging (MRI) | December 07, 2017
Max Wintermark, M.D., professor of radiology and chief of neuroradiology, Stanford Hospital and Clinics, discussed MRI...
News | Contrast Media | October 10, 2017
October 10, 2017 — Guerbet announced it will be taking part in the 65th edition of the Journées Francophones de...
Image courtesy of Bayer
Feature | Contrast Media | October 04, 2017 | By Dave Fornell
Over the past decade, several clinical studies have shown gadolinium-based magnetic resonance imaging (MRI) contrast...
Sponsored Content
Characteristics nephrologists associate with renal high-risk patients. (n=13)
Feature | Contrast Media | September 05, 2019
The global rise in chronic disease has significantly increased demand for diagnostic imaging procedures, and in turn,...
News | Contrast Media | September 12, 2017
September 12, 2017 — The U.S. Food and Drug Administration’s (FDA) Medical Imaging Drugs Advisory Committee (MIDAC)...
News | Contrast Media | September 07, 2017
September 7, 2017 — The U.S. Food and Drug Administration (FDA) held a meeting of the Medical Imaging Drugs Advisory...
Technology | Magnetic Resonance Imaging (MRI) | September 06, 2017
September 6, 2017 — Guerbet LLC USA announced that the U.S. Food and Drug Administration (FDA) has approved Dotarem (...
Sponsored Content
Power injectors can improve efficiency and patient safety, for example, ensuring that contrast agent is not wasted due to the lack of a saline bolus. Image courtesy of Lior Molvin
Blog | Contrast Media | July 31, 2019
Patient safety and operational efficiency are behind the development of modern contrast media, selection and...
News | Contrast Media | August 29, 2017
August 29, 2017 — The European Medicines Agency (EMA) issued a final opinion that recommended restricting the use of...
News | Contrast Media | August 15, 2017
August 15, 2017 — The International Society for Magnetic Resonance in Medicine (ISMRM) has provided new guidance in the...
Feature | Contrast Media | July 28, 2017 | By Dave Fornell
Here are several updates in medical imaging contrast media agents. Two of the biggest news items were related to safety...
Sponsored Content
Image courtesy of Lior Molvin
Blog | Contrast Media | July 15, 2019
Contrast agents improve every kind of medical image from computed tomography (CT) to magnetic resonance imaging (MR),...
News | Contrast Media | July 18, 2017
July 18, 2017 — Guerbet recently announced that it will phase out sales throughout the world of two products: Hexabrix...
News | Contrast Media | July 17, 2017
July 17, 2017 — The American College of Radiology (ACR) recently revised its authoritative guide for the safe and...
Technology | CT Angiography (CTA) | June 16, 2017
June 16, 2017 — The U.S. Food and Drug Administration (FDA) has expanded the indication for GE Healthcare’s imaging...
Feature | Magnetic Resonance Imaging (MRI) | May 25, 2017
May 25, 2017 — A U.S. Food and Drug Administration (FDA) review of the safety ramifications of gadolinium-based...
The ZD2-Gd probe, represented by the orange ball and green arrow, binds to the EDB-FN in the prostate cancer cells with high metastatic potential. This results in a strong MRI signal (upper right). Prostate cancer cells with low metastatic potential have no EDB-FN and so there is no MRI signal (lower right). Credit: Han, et al., Bioconjug Chem-Apr-2017
News | Prostate Cancer | May 24, 2017
May 24, 2017 — A research team funded by the National Institute of Biomedical Imaging and Bioengineering (NIBIB) has...
News | Magnetic Resonance Imaging (MRI) | May 03, 2017
May 3, 2017 — Scientists from the National University of Singapore (NUS) have developed a novel nanodiamond-based...
Sponsored Content | Case Study | Contrast Media Injectors | April 13, 2017
Improving Efficiency and Reducing Waste
The volume of computed tomography (CT) imaging exams continues to grow in the...
News | Contrast Media | March 13, 2017
March 13, 2017 — The Pharmacovigilance Risk Assessment Committee (PRAC) of the European Medicines Agency recently...
